Beyond Air (NASDAQ:XAIR) Posts Quarterly Earnings Results, Misses Estimates By $0.15 EPS

Beyond Air (NASDAQ:XAIR) announced its quarterly earnings results on Monday. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.15), Zacks reports. Beyond Air had a negative return on equity of 232.61% and a negative net margin of 880.72%. Beyond Air updated its FY 2026 guidance to EPS.

Beyond Air Trading Down 1.1%

Shares of Beyond Air stock traded down $0.02 during trading hours on Monday, hitting $1.74. The company’s stock had a trading volume of 383,607 shares, compared to its average volume of 1,073,782. The stock has a market cap of $13.80 million, a price-to-earnings ratio of -0.15 and a beta of 0.30. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.71 and a current ratio of 3.24. Beyond Air has a twelve month low of $1.64 and a twelve month high of $13.52. The firm has a fifty day moving average of $2.31 and a 200-day moving average of $3.04.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Beyond Air stock. Geode Capital Management LLC grew its stake in Beyond Air, Inc. (NASDAQ:XAIR) by 1.5% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 838,319 shares of the company’s stock after acquiring an additional 12,598 shares during the period. Geode Capital Management LLC owned about 18.07% of Beyond Air worth $144,000 as of its most recent filing with the SEC. Institutional investors own 31.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on XAIR. D Boral Capital upgraded Beyond Air to a “strong-buy” rating in a research note on Thursday, July 17th. D. Boral Capital reaffirmed a “buy” rating and set a $11.00 price objective on shares of Beyond Air in a report on Thursday, August 21st. Wall Street Zen cut shares of Beyond Air from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Beyond Air in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $11.00.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.